SCHEMBL21426166

SCHEMBL21426166

CC(C)=CCCC1(C)C=Cc2c(cc(C)c(C(=O)O)c2O)O1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 8/20 0.88
APP P05067 2/20 0.88
SLC6A2 P23975 2/20 0.71
HRH1 P35367 1/20 0.71
OPRM1 P35372 1/20 0.71
TRPA1 O75762 1/20 0.53
LDHA P00338 1/20 0.53
CNR1 P21554 1/20 0.53
SLC6A4 P31645 1/20 0.53
CNR2 P34972 1/20 0.53
SLC6A3 Q01959 1/20 0.53
TRPM8 Q7Z2W7 1/20 0.53
TRPV1 Q8NER1 1/20 0.53
TRPV3 Q8NET8 1/20 0.53
TRPV4 Q9HBA0 1/20 0.53
TRPV2 Q9Y5S1 1/20 0.53
ALOX5 P09917 3/20 0.51
PTGS1 P23219 1/20 0.50
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29467209 1.00 PTPN1 (0.88) PTPN1APPSLC6A2HRH1OPRM1
Daurichromenic Acid SCHEMBL30125504 0.94 PTPN1 (1.00) PTPN1APPSLC6A2HRH1OPRM1
Daurichromenic Acid SCHEMBL29424248 0.94 PTPN1 (1.00) PTPN1APPSLC6A2HRH1OPRM1
Daurichromenic Acid SCHEMBL30125511 0.94 PTPN1 (1.00) PTPN1APPSLC6A2HRH1OPRM1
Daurichromenic Acid SCHEMBL30125509 0.94 PTPN1 (1.00) PTPN1APPSLC6A2HRH1OPRM1
SCHEMBL30125514 0.94 PTPN1 (1.00) PTPN1APPSLC6A2HRH1OPRM1
Daurichromenic Acid SCHEMBL11218399 0.94 PTPN1 (1.00) PTPN1APPSLC6A2HRH1OPRM1
Daurichromenic Acid SCHEMBL30125505 0.94 PTPN1 (1.00) PTPN1APPSLC6A2HRH1OPRM1
SCHEMBL25560683 0.88 SLC6A2 (0.83) PTPN1APPSLC6A2HRH1OPRM1
SCHEMBL23363576 0.86 SLC6A2 (0.87) PTPN1APPSLC6A2HRH1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024148117-A2 METHODS OF TREATING NEURODEGENERATIVE DISEASES OR CONDITIONS FLORASCIENCE INC. (US) 2024-07-11 WO disclosed
US-20240026392-A1 BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS GINKGO BIOWORKS, INC. (US) 2024-01-25 US disclosed
US-20230340446-A1 BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS GINKGO BIOWORKS, INC. (US) 2023-10-26 US disclosed
US-20230137139-A1 BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS GINKGO BIOWORKS, INC. (US) 2023-05-04 US disclosed
US-20220195472-A1 BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS GINKGO BIOWORKS, INC. (US) 2022-06-23 US disclosed
WO-2020031179-A1 METHODS FOR SYNTHESIS OF CANNABINOID COMPOUNDS BEETLEBUNG PHARMA LTD. (IL) 2020-02-13 WO disclosed
WO-2019190945-A1 BIOSYNTHESIS OF OLIVETOLIC ACID WILLIAM MARSH RICE UNIVERSITY (US) 2019-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137139-A1 BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS CNR1, CNR2, GGPS1 PTPN1 4444/4885APP 2662/4885SLC6A2 2386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.